/ Print /

Pharmacies

How health execs can partner with pharmacists to address opioidsDirector of medication safety and quality for the American Society of Health-System Pharmacists shares how providers can better work with pharmacists to address the opioid epidemic.
The top three pharmacy challenges of 2018Find out what challenges top the list, and what analysts say can be done about them.
Will biosimilars deliver on expectations?This might be the year when it becomes clear, perhaps painfully so, whether or not biosimilars can deliver on cost savings expectations.
Autoimmune drug pipeline highlightsMore targeted therapies for autoimmune diseases are on the horizon. Here’s what to anticipate in 2018.
Four PBM programs poised to rein in the opioid epidemicPBMs are in a unique position to help curb opioid abuse. Here are four programs that demonstrate promising outcomes.
Opioid crisis legal ramifications: How to protect your healthcare organizationOverprescribing by just one practitioner can lead to an untoward outcome that may readily affect the entire healthcare facility.
New patient-centered tool could help measure value in healthcareThe Innovation and Value Initiative launched the Open-Source Value Project, creating tools that help payers, providers, and healthcare systems make informed and patient-centered decisions that produce better health outcomes.
Healthcare leaders must step up to fix the opioid epidemicHealthcare executives have a unique leadership role to play in addressing the opioid crisis. Here’s what you need to do now.
Is there a simple fix for the Part D discount program?A poll from the Biosimilars Council, a division of the Association for Accessible Medicines, has interesting findings about placing biosimilars and branded biologics on a level playing field to save money.
New RA drugs and pipeline developments to watchTreating RA is a work in progress. Here’s what you need to know.